SEC Form 4 · accession 0001992352-26-000007
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kathryn Guarini
Director
Period of report
Sep 2, 2026
Accepted (ET)
Sep 3, 2026 · 4:47 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 2, 2026 | M | 400 | $719.37 | A | 1,003 | D | |
| Common Stock | Sep 2, 2026 | S | 400 | $850.00 | D | 603 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2 | $719.37 | Sep 2, 2026 | M | 400 | D | — | Jan 2, 2035 | Common Stock | 400 | 1,158 | D |
Explanation of responses
- F1Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2026.
- F2On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.